Oracle (NYSE: ORCL) and AstraZeneca announced a partnership to advance AI-enabled healthcare solutions focused on real-world data and clinical research. The collaboration aims to improve identification of eligible patients for clinical trials and to speed up evidence generation from real-world datasets. Both companies plan to link research outputs directly into care delivery workflows across several therapeutic areas, including chronic and complex diseases. The Oracle and AstraZeneca AI-enabled healthcare partnership is a material shift that investors may want to weigh against other findings. Check out 3 warning signs (1 major) that Oracle investors should know about.
Головну думку ми показуємо публічно. Створіть безкоштовний акаунт, щоб читати повну статтю, зберігати її, обговорювати та поєднувати з ринковим і OSINT-контекстом.